ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan.
about
Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate.Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytesADAMTS4 and ADAMTS5 knockout mice are protected from versican but not aggrecan or brevican proteolysis during spinal cord injury.Expression of genes encoding extracellular matrix proteins: a macroarray study.Calcium pentosan polysulfate directly inhibits enzymatic activity of ADAMTS4 (aggrecanase-1) in osteoarthritic chondrocytes.Extracellular proteases as targets for drug developmentGreen tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. [corrected].Quantitative MRI as a diagnostic tool of intervertebral disc matrix composition and integrity.Metalloproteases as potential therapeutic targets in arthritis treatment.Conserved sequence in the aggrecan interglobular domain modulates cleavage by ADAMTS-4 and ADAMTS-5.The role of ADAMTSs in arthritisRole of Sp1 transcription factor in Interleukin-1-induced ADAMTS-4 (aggrecanase-1) gene expression in human articular chondrocytes.The retinoic acid binding protein CRABP2 is increased in murine models of degenerative joint disease.Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice.Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage.Therapeutics in Osteoarthritis Based on an Understanding of Its Molecular Pathogenesis.Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice.
P2860
Q33303263-9D3EEF0C-B29F-412B-956F-91AEB5D02FDDQ33549568-501F77B2-D480-46A6-B8AA-C5A4F2F9995CQ33914563-4523D7AD-0E84-43F3-85C0-1F2C6BE358F7Q34556688-4644C73D-6842-47E9-AA0C-3719C66323ABQ34803185-BBCA5C6D-856D-40E4-ABA5-907203AB6008Q35116202-9A2090E8-246A-454D-B04D-09ACAD88CAA0Q35135845-B0A2D609-A941-4341-974D-93C824611B5EQ36985345-805B5A53-9538-46FE-8FDE-FA560F58D406Q37030862-9B561283-F9BE-40FC-97BF-6ED77645AA85Q37130548-C9996901-A3DC-4396-9BF2-FAFE4E6C29AEQ37825835-00EAA1AF-A86B-4A40-B193-CC87406D24A2Q38330477-29928D71-92DC-49A9-87A3-E25843C72F9CQ43120812-42DE01FD-6997-416A-A0B6-AB36693806AFQ46949433-DDD14338-16A0-4097-82CB-03668BE5C1B6Q50280462-189751C1-58BE-4604-8C54-01A2B27D62AAQ52679053-0F70CE1E-20CE-4359-9B78-8B34DF988893Q54418168-768E4594-D1A0-437D-AE12-4E4867A12644
P2860
ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@ast
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@en
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@nl
type
label
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@ast
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@en
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@nl
prefLabel
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@ast
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@en
ADAMTS-5 deficiency does not b ...... lfate-rich region of aggrecan.
@nl
P2093
P2860
P356
P1476
ADAMTS-5 deficiency does not b ...... ulfate-rich region of aggrecan
@en
P2093
Charlotte J East
Fraser M Rogerson
Suzanne B Golub
P2860
P304
P356
10.1074/JBC.M605750200
P407
P577
2007-01-25T00:00:00Z